title: [Two Cases of ER-Positive Postmenopausal Breast Cancer That Increased in Size during Neoadjuvant Hormone Therapy].
abstract: The first patient was a 62-year-old woman who was referred to our hospital with the complaint of a left breast tumor. She was diagnosed with invasive ductal carcinoma(T1N0M0, stage I). The tumor was ER-positive, PgR-negative, and HER2- negative. She was treated with toremifene, letrozole, and anastrozole as neoadjuvant hormone therapy for 4 months, but the tumor increased in size. The clinical response was judged as progressive disease, and a left partial mastectomy and axillary lymph node dissection were performed. Chemotherapy and radiotherapy were performed after surgery. The second patient was a 68-year-old woman who was referred to our hospital with the complaint of a right breast tumor. She was diagnosed as invasive ductal carcinoma(T1N0M0, stage I). The tumor was ER-positive, PgR-negative, and HER2-negative. She was treated with letrozole as neoadjuvant hormone therapy for 4 months, but the tumor increased in size. The clinical response was judged as progressive disease, and a right partial mastectomy and axillary lymph node dissection were performed. Chemotherapy and radiotherapy were performed after surgery. Although the evidence is still insufficient, with neoadjuvant hormone therapy for hormone-sensitive breast cancer, improved tumor shrinkage and breast conservation have been reported. We experienced two cases in which the tumor increased in size during neoadjuvant hormone therapy; however, even though these cases showed no apparent effect, chemotherapy may be effective in future cases.
authors.affiliation: Dept. of Surgery, Toyota Kosei Hospital.
authors.forename: Takanori
authors.initials: T
authors.lastname: Jinno
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Kurumiya
authors.forename: Tae
authors.initials: T
authors.lastname: Niwa
authors.forename: Ei
authors.initials: E
authors.lastname: Sekoguchi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Kawai
authors.forename: Muneyasu
authors.initials: M
authors.lastname: Kiriyama
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000737:chemistry / Q000473:pathology / Q000628:therapy*; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry / Q000628:therapy*; D059248:Chemoradiotherapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D017698:Postmenopause; D011960:Receptors, Estrogen / Q000032:analysis
chemical_list: D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen